文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

慢性肾脏病

Chronic kidney disease.
PubMed 文献 · Lancet · 2021-06-24
一句话结论CKD无法治愈且并发症负担高,应以饮食调整、靶向药物和避免肾损伤等保肾策略延缓进展。

本文综述慢性肾脏病的保肾管理。CKD在成人尤其糖尿病和高血压人群中常见,进展性且病死率高。以植物为主、低蛋白低盐饮食可能减轻肾小球高滤过;调节肾内血流动力学的药物(如RAAS通路调节剂和SGLT2抑制剂)可不依赖降压和降糖而降低肾小球内压以保护肾功能;非甾体盐皮质激素受体拮抗剂可能通过抗炎抗纤维化机制护肾。管理心血管风险、减少感染和预防急性肾损伤至关重要。需透析时可考虑增量式过渡以可能更久保留残余肾功能。

要点

  • CKD在成人尤其糖尿病和高血压人群中常见,进展性且无法治愈,病死率高,保肾可改善结局。
  • 以植物为主、低蛋白低盐饮食可能减轻肾小球高滤过、延长保留肾功能,并可能改善酸碱平衡和肠道菌群。
  • RAAS通路调节剂和SGLT2抑制剂可不依赖血压和血糖控制,通过降低肾小球内压保护肾功能。
  • 非甾体盐皮质激素受体拮抗剂可能通过抗炎或抗纤维化机制护肾。
  • 管理CKD相关心血管风险、减少感染、预防急性肾损伤至关重要;需透析时可考虑增量式过渡以可能更久保留残余肾功能。

适用人群与场景

  • 一般成人人群,尤其是糖尿病和高血压患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 非药物策略:饮食和生活方式调整,如以植物为主、低蛋白、低盐饮食,可能减轻肾小球高滤过并延长保留肾功能。
  • 药物治疗:RAAS通路调节剂和SGLT2(SLC5A2)抑制剂可不依赖血压和血糖控制,通过降低肾小球内压保护肾功能。
  • 其他新型药物:非甾体盐皮质激素受体拮抗剂可能通过抗炎或抗纤维化机制护肾。
  • 部分肾小球和囊性肾病可受益于疾病特异性治疗。
  • 管理CKD相关心血管风险、减少感染风险、预防急性肾损伤。
  • 当肾脏替代治疗不可避免时,可考虑增量式过渡到透析,可能更久保留残余肾功能。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 本文为综述,汇总保肾策略:以植物为主、低蛋白低盐饮食可能减轻肾小球高滤过并延长保留肾功能;RAAS通路调节剂和SGLT2抑制剂可不依赖降压降糖而降低肾小球内压护肾;非甾体盐皮质激素受体拮抗剂可能通过抗炎抗纤维化护肾;需透析时增量式过渡可能更久保留残余肾功能。

证据类型、等级与局限

  • 综述;原文未给出证据等级或推荐强度;局限:非系统评价,未提供具体研究数据或样本量。

对床旁实践的改变

  • 对CKD尤其在糖尿病和高血压患者中,可考虑以植物为主、低蛋白低盐饮食以可能延缓肾功能丧失。
  • 可使用RAAS通路调节剂和SGLT2抑制剂,其护肾作用不依赖血压和血糖控制。
  • 需重视管理心血管风险、减少感染和预防急性肾损伤。
  • 透析不可避免时可考虑增量式过渡以可能更久保留残余肾功能。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Chronic kidney disease is a progressive disease with no cure and high morbidity and mortality that occurs commonly in the general adult population, especially in people with diabetes and hypertension. Preservation of kidney function can improve outcomes and can be achieved through non-pharmacological strategies (eg, dietary and lifestyle adjustments) and chronic kidney disease-targeted and kidney disease-specific pharmacological interventions. A plant-dominant, low-protein, and low-salt diet might help to mitigate glomerular hyperfiltration and preserve renal function for longer, possibly while also leading to favourable alterations in acid-base homoeostasis and in the gut microbiome. Pharmacotherapies that alter intrarenal haemodynamics (eg, renin-angiotensin-aldosterone pathway modulators and SGLT2 [SLC5A2] inhibitors) can preserve kidney function by reducing intraglomerular pressure independently of blood pressure and glucose control, whereas other novel agents (eg, non-steroidal mineralocorticoid receptor antagonists) might protect the kidney through anti-inflammatory or antifibrotic mechanisms. Some glomerular and cystic kidney diseases might benefit from disease-specific therapies. Managing chronic kidney disease-associated cardiovascular risk, minimising the risk of infection, and preventing acute kidney injury are crucial interventions for these patients, given the high burden of complications, associated morbidity and mortality, and the role of non-conventional risk factors in chronic kidney disease. When renal replacement therapy becomes inevitable, an incremental transition to dialysis can be considered and has been proposed to possibly preserve residual kidney function longer. There are similarities and distinctions between kidney-preserving care and supportive care. Additional studies of dietary and pharmacological interventions and development of innovative strategies are necessary to ensure optimal kidney-preserving care and to achieve greater longevity and better health-related quality of life for these patients.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021. PMID: 34175022. doi:10.1016/S0140-6736(21)00519-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。